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ABSTRACT 
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a mental 
health disorder characterized by functional impairment due to symptoms of 
inattention, impulsivity, and hyperactivity. Psychostimulant medications 
effectively reduce these symptoms, however there is little evidence regarding 
the factors associated with use of different types of stimulant medications. 
Objective: To investigate factors associated with sustained release (SR) 
versus immediate release (IR) stimulant prescription for pediatric ADHD.  
Methodology: A cross-sectional observational study was conducted using the 
2012 National Ambulatory Medical Care Survey (NAMCS), a nationally 
representative sample of physician office visits. Independent predictors of SR 
stimulant medication prescription, as compared to IR stimulant prescription, 
were identified from logistic regression models. 
Results: Our data set contained visits representative of 105,548,504 visits with 
an associated age of 4-17 years old (11.39% of all visits). Of these pediatric 
visits, there were 7,088,227 visits (7.56%) with an ADHD diagnosis code (ICD-
9: 314.00, 314.01). The majority of pediatric ADHD visits were male 
(n=5,155,695, 72.74%). The most frequent age groups were 7 to 11 years 
(n=3,374,121, 47.60%) and 12-17 years (n=46,097, 42.97%), while the 4-6 
year age group was less frequent (n=668,010, 9.42%). The most frequent race 
was White (n=4,771,295, 67.31%), while less frequent were Black race 
(n=1,229,675, 17.35%) and Hispanic race (n=956,710, 13.50%). The most 
frequent office region was the South (n=3,221,211, 45.44%). The most 
frequent pay types were private insurance (n=3,427,928, 48.36%) and 
Medicaid (n=2,473,735, 34.90%).  
After applying our study inclusion criteria, there were 4,617,709 
pediatric visits with IR or SR prescriptions. Of this visit sample, 3,431,741 had 
sustained release (74.35%) and 1,185,968 visits had immediate release 
stimulant prescriptions (25.68%). There were 1,969,116 visits with a 
combination of SR/IR (42.64%), which we included as SR in our modeling. 
Our logistic modeling approach identified a number of non-significant 
sociodemographic predictors of SR prescription, relative to IR prescription. 
Compared with the 7-11 year old age group, the 12-17 year old group was 
70% more likely to have a SR vs IR prescription (OR=1.695), while the 4-6  
year old group was roughly 70% less likely to have SR than IR (OR=0.359). 
Relative to those with white race/ethnicity, those of black race (OR=2.183), 
Hispanic race (OR=2.223), and "Other" race (OR=2.717) had a non-significant 
but doubled likelihood of receiving an SR vs IR only prescription. Our logistic 
approach did not find evidence that sex or ADHD subtype were significant 
predictors of SR vs IR stimulant prescription. Overall, this modeling approach 
did not identify any significant sociodemographic predictors of SR vs IR only 
use
Conclusions: In our nationally representative sample of pediatric ADHD office 
visits, visits of adolescent age or those with comorbid anxiety disorder had a 
higher likelihood of a SR stimulant drug mention than an IR mention. In 
contrast, visits with a diagnosis of autism and those in the Western region 
were less likely to have SR relative to an IR stimulant prescription. We did not 
find evidence to support disparities in SR versus IR stimulant prescriptions in 
visits of Black, Hispanic, or female children. These findings documented 
similarities and differences in ADHD medication prescription across 
sociodemographic groups that may be helpful for identifying office visits with a 
predisposition towards SR or IR stimulant prescription and to further 
understand the choice of ADHD drug for childhood ADHD.  
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CHAPTER 1 
 
Background 
Attention deficit hyperactivity disorder (ADHD) is defined by persistent 
and developmentally inappropriate problems with attention, impulsivity, and 
hyperactivity that cause functional life impairments.1,2 Children with ADHD 
suffer functional impairments because of symptoms such as forgetfulness, 
distractibility, excessive fidgeting, and disorganization.3  Numerous studies 
have demonstrated ADHD is effectively and safely treated by a variety of 
medications including stimulants like methylphenidate and amphetamine salts, 
or the non-stimulant atomoxetine.4-6   
There is a national childhood ADHD prevalence of roughly 10%, which 
represents over five million children.3,7,8 There is an estimated cost burden of 
ADHD between $36 and $52 billion dollars in 2005, due to a loss of 
productivity in those with ADHD.9-14 The societal cost burden includes a loss in 
the productivity of students and workers, totaling an estimated $3.7 in adult 
work costs, and increased healthcare costs due to mental health 
comorbidities, unintended injuries, and utilization of behavioral therapy.11,12,15-
17  Further, relative to their non-ADHD classmates, the five million US children 
with ADHD are less likely to succeed in academics13,14  and more likely to 
struggle to maintain healthy friendships and familial relationships.9,10  For 
instance, children with ADHD report almost 3 times as many peer problems as 
those without ADHD (21.1% vs 7.3%) and are almost 10 times as likely to 
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have difficulties with friendships (20.6% vs 2.0%).12 Because these chronic 
impairments can lead to consequences like poor grades, low self-esteem, and 
hampered social lives, it is understandable that those with ADHD are more 
likely to develop comorbidities like depression18,19, anxiety20, and 
obesity.11,21,22  
In 2011, the American Academy of Pediatrics (AAP) published 
guidelines concerning the evaluation, diagnosis, and treatment of pediatric 
ADHD.23 This document highlights the strength of evidence for diagnosis of 
ADHD via the diagnostic criteria in the Diagnostic and Statistical Manual of 
Mental Disorders Version V (DSM-V), the importance of evaluation of common 
comorbidities like anxiety and depression, and acquiring symptom information 
from different perspectives including parents, teachers, and other clinicians. 
Concerning the 4-5 year age group, the AAP suggests that behavioral therapy 
should be first and psychostimulant treatment methylphenidate second, 
though some research supports the effectiveness of medication alone.4,10,14 
These guidelines also suggest that children 6 years or older may have ADHD 
medications alone, therapy alone, or a combination of both.  
Regarding medication options, there is a plethora of evidence 
demonstrating the effectiveness of stimulants for the treatment of ADHD. 
Since the 1937 study of Charles Bradley, stimulants have been proven to be 
effective for the reduction of hyperactivity, impulsiveness, and short attention 
span24. In his original Bradley's study of stimulants for the treatment of severe 
headaches from pneumoencephalograms, Bradley observed a striking 
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improvement in the behavior of numerous patients. Bradley's subsequent 
systematic trial of stimulant use for the alteration of behavior noted 
"remarkably improved school performance." This groundbreaking study 
inspired many subsequent studies of stimulants and changed the treatment of 
what is known today as ADHD25.  
Treatment of ADHD with psychostimulants, such as methylphenidate 
(brand name Ritalin) and mixed amphetamine salts (brand name Adderall), 
has been proven effective for ADHD symptom reduction.4,6,9,26-29 These 
stimulant medications affect dopamine and norepinephrine reducing 
inattention, impulsivity, and hyperactivity. Though side-effects such as 
increased heartrate and blood pressure, tics, insomnia, and agitation may be 
bothersome, the evidence suggests stimulants are safe for chronic use in 
children older than four years.23,29 A few studies have shown treatment 
benefits in meaningful endpoints like academic success.13,14,30 Relative to 
behavioral therapy, ADHD medication has been shown to be cost effective in 
symptom reduction and more cost-effective than behavior therapy alone.26,31-33 
The main non-stimulant treatment for ADHD is atomoxetine.  This non-
stimulant may be preferable for children with ADHD and certain comorbidities, 
such as comorbid anxiety disorder, substance abuse disorder, and tics.5,34,35 
There are a variety of formulations of the stimulant medications which 
differ primarily in their duration of effect. Immediate release (IR) stimulants 
may last 3-4 hours and require multiple daily doses, whereas sustained 
release (SR) stimulants may last upwards of 12 hours and have a longer 
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duration of effect and slightly different modes of delivery, factors which may 
contribute to slight improvements in adherence.36 For instance, 
lisdexamfetamine (brand name Vyvanse) is an SR stimulant pro-drug which 
requires lysine cleavage in the red blood cells to become the active 
dextroamphetamine. Thus, lisdexamfetamine has both a long duration of effect 
and has a reduced potential for abuse, offering a contrast with mixed 
amphetamine salt which is racemic and not in ingested in a pro-drug form.  
Stimulants have their drawbacks, however, as they may cause side-
effects including increased heartrate and blood pressure, decreased appetite 
and trouble sleeping.37 The use of IR medication may lead to uncomfortable 
dose peaking with increases in adverse effects, increased inconvenience of 
multiple daily doses, and a lower adherence rate relative to extended release 
stimulants38. Since the introduction of SR medication formulations, such as 
long-acting methylphenidate (brand name Ritalin-LA) in 2002 and extended-
release mixed amphetamine salts (brand name Adderall XR) in 2001, SR 
formulation use has increased.39 This trend may be due to improved drug 
adherence, patient convenience, and lower peak and higher trough dose 
concentrations relative to IR formulations. Therefore, patients on SR 
medications may have more comfortable dose peaking and improved 
adherence.40-43 Suffice to say, as our understanding of ADHD has grown, so 
too has the number of ADHD drugs, with over twenty medications and 
formulations approved by the FDA for treatment of ADHD.  
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While prescription of these SR formulations may yield improvements in 
adherence, some SR formulations may be more expensive than IR 
formulations. Considering formulation price differences, there may be 
sociodemographic disparities in the prescription of these more expensive 
formulations. One 2013 study of Florida Medicaid claims found no racial 
disparity in SR medication prescriptions.36  However, due to a limited and non-
generalizable sample, this study was not applicable to the American 
population at large.  Further, although numerous studies have compared the 
proportions of any medication use in different racial or socioeconomic groups, 
we have not identified any studies of factors associated with SR versus IR 
prescription in nationally representative data derived from medical charts 
versus information recall.4,14,41,43,44  
Our cross-sectional analysis and predictive modeling of ADHD 
medication prescriptions may be a useful addition to this literature. While one 
previous study provided useful information on the prevalence of ADHD 
diagnosis and medication prescription, no published NAMCS study has built a 
predictive model of SR treatment.45  Furthermore, the majority of medication 
treatment studies in other data sources did not examine predictors of specific 
types of medication prescription. Finally, there are few studies in the literature 
of predictors SR vs IR stimulant prescription and those few studies of 
medication type used limited regional datasets to make predictions.38,43 
To address these evidence gaps, the purpose of this study was to 
identify predictors of SR versus IR stimulant prescription in the United States. 
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To do so, we conducted a cross-sectional observational study of a nationally 
representative survey of 2012 physician office visits. Our research question 
was whether or not there are sociodemographic predictors of SR versus IR 
stimulant prescription in the US pediatric population. Potential predictors were 
identified from a set of sociodemographic covariates including age, sex, pay 
type, office region, race, and physician specialty. This analysis was strong in 
its national generalizability, up-to-date data source, and use of multivariate 
modeling for adjustment of odds ratios. While our study had limitations due to 
a lack of patient-level data in the NAMCS and due to the relatively small 
pediatric ADHD sample present in the 2012 data, we are confident our findings 
will be a useful piece of evidence for prescribing patterns in the United States.  
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CHAPTER 2 
 
LITERATURE REVIEW 
Literature Review  
Methods for Literature Search  
To ensure this project targeted specific evidence gaps related to SR 
medication treatment disparities in childhood ADHD, a thorough literature 
review was conducted with the PubMed Medical Subject Heading system 
(MeSH) terms: ("Attention Deficit Disorder with Hyperactivity/drug therapy") 
and ("healthcare disparities" OR "epidemiology" OR "Delayed-Action 
Preparations"). To ensure our search examined only childhood ADHD (ages 4-
17), the PubMed filter "Child" was utilized. We chose to search the literature 
from January 1987 to September 2015 because throughout this period, 
hundreds of studies have been published while subtle changes occurred in the 
DSM III-R in 1987, the DSM IV in 1994, and the current DSM-V, published in 
2013. The year 1987 was an appropriate starting date for our search since that 
year the disorder title was changed from ADD to ADHD and there was more 
robust empirical validation of diagnostic criteria.  
From over 10,000 study titles reviewed in the literature search, 33 
articles relevant to this study of sustained release medication disparities were 
included (Figure 1). From 10,000 titles, studies of adults, genetics, 
neuroimaging, historical analyses, editorials, opinions, and commentaries 
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were excluded. The abstracts of approximately 500 relevant abstracts were 
reviewed for inclusion. After abstract review, 360 were excluded due to 
utilizing adult populations, performing a different type of study, or being a 
duplicate abstract. The full text for each included study was acquired to 
determine the evidence base on sustained release disparities.  
While numerous studies were included on the background of ADHD 
prevalence, diagnosis, and treatment, many were excluded due to lack of 
relevance to predictors of medication prescription. Moreover, several 
prevalence studies and meta-analyses of these prevalence studies were 
examined. We excluded any prevalence studies that did not analyze predictors 
of medication treatment. Nevertheless, many of these articles on prevalence 
trends have been useful in the establishment of the burden and impact of 
ADHD and we include a small synopsis of this work in order to establish the 
proper context for our work.  
Literature Review  
Trends in Treatment 
While studies are not in agreement about trends in ADHD diagnosis 
rates, there is a strong consensus that prescription medication use for ADHD 
has increased in recent years. In 2007, in broadly representative regional and 
national prescription benefit plans, Castle et al. determined that treatment 
prevalence increased 11.8% for children and adults in the period 2000-200546. 
They noted a particular increase in girls and adults. Also, this study found that 
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ER became increasingly preferred over IR from 2000-2005 and that generic 
use in children went down from 2000-2005. In 2012, Chai et al. found that 
ADHD medication use increased 46% from 2002 to 2010 and that MPH was 
the most prescribed medicine to adolescents (12-17)47. Furthermore, in 2014 
Visser et al. found the prevalence of medicated ADHD increased by 28% from 
2007-20117. Finally, Toh et al. in 2006 used the NAMCS 1993-2003 data and 
found an increase of 2.1% to 4.0%45. Therefore, if we examine medication use 
in the NAMCS in 2012, we might see the rate of drug mentions for childhood 
ADHD in the range of 4% to perhaps as much as 8%, if increases are found to 
be consistent with previous findings. These studies are generally in 
agreement: ADHD medication use has become more frequent over recent 
years. Most of these studies did not examine predictors for specific types of 
medication, but were rather simple trend analyses. Therefore, another trend 
analysis would not target evidence gaps.   
Literature Review  
Predictors of Treatment  
We examined the literature regarding predictive factors associated with 
ADHD diagnosis and treatment, including age, sex, race, insurance status, 
and region. In 2012, Lingenini et al. found that depression, anxiety, type of 
healthcare coverage, and male gender were all associated with ADHD 
diagnosis48. To do so, they used the National Survey of Children's Health 
(NSCH), which is a population-based cross-sectional survey collected via 
digital-dialing of US households from 2007-2008. Their sample included 
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91,642 children and they found that roughly 10% of parents reported their 
child had received a diagnosis at some point. Like the diagnosis, medication 
use at any prior or current time was assessed via a survey question to 
parents. Lingineni et al. found that, relative to white children, Black and 
Hispanic children were less likely to be diagnosed (OR=0.72 and OR=0.65).  
Numerous studies suggested ADHD differences in females, perhaps 
due to the lack of hyperactivity and impulsivity symptoms in some girls with 
ADHD. Froehlich et al. examined 2001-2004 NHANES data and found that 
boys were more likely to be diagnosed.49 Furthermore, there may be varying 
rates of care in groups of lower socioeconomic status and in different 
racial/ethnic groups. In their 2007 study of 2001-2004 NHANES data, 
Froehlich et al. utilized three different logistic regression models, including one 
for medication treatment amongst those with ADHD by DSM-IV criteria. They 
found that, relative to 8-11 year olds, 12-15 year olds were more than three 
times likelier (AOR=3.6, 95% CI = 1.6-8.2) to take any medication in the past 
year. Furthermore, they found that relative to white children, African-American 
(AOR = 0.7, 95% CI = 0.4-1.6) and Mexican-American (AOR = 0.6, 95% CI = 
0.2-2.0) children were less likely to have medication treatment. While this 
study does have the strength of measuring prevalence with reported 
symptoms, the small sample size (n=222) does not confer statistical 
significance to odds ratios of treatment across sociodemographic groups. 
Another study of the NHANES data by Merikangas et al. agreed with these 
findings of prevalence and rates in subgroups17. Since the NHANES dataset 
11 
 
only includes a survey question about any ADHD medication use in the past 
year, these studies did not report type of medication used, whereas our study 
will do so.  
An earlier study in 2004 by Stevens et al had similar findings on ADHD 
disparities as these NHANES studies. They found that ethnic and regional 
differences existed in ADHD diagnosis for pediatric primary care visits.50 
Relative to whites, Hispanics were less likely to be diagnosed and African-
Americans less likely to use medication. Symptomatic prevalence was higher 
for poor children, whilst medication use was more likely in the wealthiest 
children. 
Another examination of race and medication use was published in 2006 
by Zuvekas et al., which looked at trends in stimulant use and analyzed 
stimulant use in sociodemographic subgroups.54 In their 2002 data source, 
they found that females, blacks and Hispanics, and uninsured children had 
lower proportions of stimulant use relative to respectively, boys, whites, and 
those on private/public insurance. Furthermore, geographically the study found 
slight regional differences in medication use in 2002, with the South (3.4%) 
and Midwest (3.0%) having more use than the Northeast (2.7%) and the West 
(2.2%). 
While these previous studies examined diagnosis and any kind of 
treatment, they didn't address SR or IR stimulant prescription specifically. In 
2013, Saloner et al. published a highly relevant study to predictors of 
sustained release ADHD medication use36. Their data source was claims data 
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and it was limited to Florida Medicaid 96-05. The authors found that ADHD-
diagnosed minorities were less likely to utilize medication (unadjusted odds 
anywhere from 18% less likely to 22% less likely depending on year and group 
comparison). Amongst those who did use medications, they found African-
American and Hispanic children were not much less likely to use long-acting 
medications than white children (unadjusted odds from 5% to 14% less likely 
for African-Americans and 3 to 13% less likely for Hispanics).One limitation of 
this study is it does not utilize a nationally generalizable, up-to-date study 
population. For example, new medications/formulations were recently 
released, which this data did not capture (e.g. Kapvay in 2010, Quillivant XR in 
2012, and Azenys XR-ODT in 2016). Furthermore, Florida Medicaid data is 
not necessarily indicative of the national population of American children. 
Another study published in 2010 by Lang et al. primarily examined 
trends in medication but which specifically looked at short-acting vs long-
acting ADHD medications from 1994-2003 with international pharmaceutical 
claims data.39 They found that US medication expenditures for ADHD 
increased 594% from 1994-2003 largely due to price increases from 
expensive new treatments introduced in their study period. These analyses 
demonstrated that only 1% of the rise in US expenditures was due to sales 
volume, whereas 97% was due to price and 2% to residual. Therefore, we can 
see a shift towards more expensive long-acting medications in the USA before 
2012.  
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In their 2013 study of UK data of 77 individuals aged 6-18, Gormez et 
al. studied the effects of switching to MPH-SR from MPH-IR.51 They found that 
some clinicians may consider using higher doses or an additional MPH-IR 
dose to augment the effects of MPH-SR. They also supported the use of 
specialist ADHD clinics, relative to generic service centers. This built upon the 
2010 study by Thompson et al., which was a UK study that found amongst 97 
patients, 32% responded poorly to the switch and in 26 of the 97 patients, SR 
treatment was a failure and they were switched back.52 These studies highlight 
the need for monitoring patients who switch from IR to SR medications. 
Specifically regarding the superiority of SR vs IR stimulant formulations, 
there have been a few studies on the question. In 2006, Steele et al. 
conducted a randomized controlled effectiveness trial and found once-daily 
formulations are more effective in multiple outcome measures including 
remission rate53. In 2009, the Canadian Paediatric Society (CPS) put out a 
position statement that suggests extended-release (XR) medications are 
preferred over short-acting medications by both families and physicians.  
Furthermore, these authors claim that XR preparations are expensive and 
more unaffordable for disadvantaged populations.54 Along with this CPS 
position statement, the NICE organization from the UK published guidelines on 
ADHD that concluded modified-release medications are preferred over IR 
medications because of convenience, improving adherence, different 
pharmacokinetic profiles, reducing stigma, and reducing problems relating to 
schools storing drugs (guideline 1.5.5.4).55 These three studies provided 
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sufficient evidence that there are benefits for SR stimulant formulations, 
relative to IR formulations. This body of work provides the crucial evidence to 
support the central premise of our study, which is that SR may be slightly 
better than IR and questioning if there are disparities in SR prescription. 
In summary, this literature search identified the studies establishing the 
advantages of SR over IR stimulant formulations and the studies highlighting 
sociodemographic disparities in ADHD treatment. Therefore, since our study 
purpose was to examine potential predictors of healthcare disparities in ADHD 
medication treatment, our specific research question was whether or not there 
were sociodemographic predictors of SR versus IR stimulant prescription in 
the US pediatric population. Based upon our knowledge of previous literature, 
we hypothesized that there may be sociodemographic predictors of SR vs IR 
prescription including subgroups of age, sex, race, insurance status, and a 
number of other potential predictors not addressed in previous studies.  
Our study had strengths to build upon this previous literature, assessing 
prescription patterns in a nationally representative sample and providing 
adjusted odds ratios for sociodemographic predictors of prescription of 
superior medication formulations. While potentially useful to ADHD treatment 
decision-makers, our study limitations must be considered including a lack of 
longitudinal data, a lack of utilization information, and smaller analytic sample 
due to the use of only a single year of data. Nevertheless, our study may 
provide valuable information in assessing sociodemographic disparities in 
ADHD medication treatment.
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CHAPTER 3 
 
METHODS 
Study Design  
A cross-sectional study design was used, in which exposures and 
outcomes are determined at the same point in time for a given population. This 
study design allowed a broad analysis across many different levels of 
variables, which will be useful for our study of pediatric ADHD treatment 
disparities in the United States.  
Methods  
Sample  
This study examined 2012 pediatric ambulatory care visits with an 
ADHD diagnosis in the National Ambulatory Medical Care Survey (NAMCS). 
The NAMCS a nationally representative survey distributed by the Center for 
Disease Control (CDC). In the NAMCS, the basic unit of observation is the 
physician office visit; therefore the study population is only representative of 
those who visited physician offices. This data was generated by physicians 
recording information about office visits in a randomly assigned week on a 
survey form.  
This data includes numerous variables including diagnoses, medication 
codes, procedure codes, and sociodemographic variables. Diagnoses are 
16 
 
indicated by the International Classification of Diseases (ICD-9) diagnostic 
codes. Medication codes, including those for generic and brand name drugs, 
do not indicate prevalent use, incident use, or drug switching, nor dosage or 
actual drug utilization. Sociodemographic information is encoded in categorical 
variables, though there may be numerous missing values including race in 
32.9% of visits. The NAMCS does provide weights, strata, and cluster 
information so that SAS 9.3 can produce nationally representative estimates of 
sociodemographic information. 
In the 2012 NAMCS there were a total of 76,630 unweighted visits and 
928,629,953 weighted visits. There were 8,694 unweighted visits and 105, 
548,504 weighted visits with an age of 4-17. We applied inclusion criteria to 
create a study sample of pediatric ADHD visits with stimulant prescription 
(Figure 2). Our analytic sample was constructed as follows: 
1) Visits with an age between 4 and 17 and with an ICD-9 code of 314.0, 
314.00, or 314.01 were included as the pediatric ADHD visit population. 
2) Medication information was identified by medication codes and drug ID 
codes, identified in the appendices.  
a. Visits with Adderall XR, Ritalin LA, Focalin XR, Methylin-ER, Ritalin-
SR, and Vyvanse were included in the SR group of interest. 
b. Those with only Ritalin, Focalin, Adderall, Methylin, or 
Methamphetamine were included in the IR reference group. 
c. Those with a combination of IR and SR mentions will be considered 
as SR, thus our model will compare "Any SR" vs." IR Only" 
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d. Those with a generic code for methylphenidate or mixed-
amphetamine salt combo were included as IR. 
With these pediatric ADHD stimulant visits, we conducted a cross-
sectional study to determine any sociodemographic factors associated with 
sustained release (SR) versus immediate release (IR) stimulant prescriptions. 
Methods  
Descriptive Statistics 
Descriptive statistics were used to characterize the study population by 
frequency and percentage. These analyses examined all pediatric visits with 
an ADHD diagnosis as well as those visits with certain types of medication 
prescribed like non-stimulants, SR, and IR stimulants. We used standard 
NAMCS nationally representative weighing procedures to calculate medication 
treatment in the independent variables including age group, sex, insurance 
status, office region, race, and physician specialty. We also included 
comorbidities relevant to ADHD, including obesity56, asthma15, anxiety5, 
depression48, or autism.57 While these comorbidities were examined in our 
descriptive statistics, they were not included in our modeling approach since 
the research question for this study specifically targeted sociodemographic 
disparities.  
The national weighing process in the NAMCS utilized information on the 
data cluster, data stratum, and patient weight for each NAMCS observation. 
Cluster and strata adjustments are necessary due to the complex multi-stage 
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sample design of the survey. These design variables in the NAMCS allow for 
creation of nationally representative estimates with appropriate variance 
estimation for surveys. A priori power analyses were not conducted since 
these statistical tests utilized readily available data entries.  
To compare treatment proportions in population subgroups, we used 
basic statistical tests of difference. To test for differences in the proportion of 
SR stimulant used across different values of categorical variables, the 
Pearson Chi-square (χ2) test or Fisher's exact test was utilized, if the 
assumptions for the χ2 were not met. The question for each independent 
variable was whether or not proportions of that variable differed significantly 
for those with SR vs. those with IR. While independent variables related to 
diagnoses were dichotomous, for the independent variables, including race, 
pay type, age group, physician specialty, and office region, overall p-values for 
the entire variable were assessed. For the only continuous variable, age, a t-
test was used to determine if SR medication prescription has a relationship 
with age.  
For all descriptive analyses, the 2-tailed alpha level of significance was 
set at 0.05. All statistical tests were conducted using SAS 9.3 (SAS Institute 
Inc., Cary, NC, USA).  
Methods  
Multivariate Regression Modeling 
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To address the evidence gap regarding the predictors of SR ADHD 
medication prescription, we utilized a predictive logistic regression modeling 
approach. This method allowed us to examine the associations between the 
dependent variable, SR stimulant prescription, and the predictors of interest 
including sex, age, racial and ethnic background, geographic region, pay type, 
and physician specialty. For each predictor of interest, our logistic regression 
model produced adjusted odds ratios comparing the relative likelihood of SR 
stimulant prescriptions vs. those with only IR prescriptions. We constructed 
both an initial multivariate model and we sequentially removed variables using 
an iterative, manual process to remove covariates that are not predictive of SR 
vs IR stimulant prescription. This reduced model was compared to the larger 
initial multivariate model using the AIC, c-statistic, and the Hosmer-Lemeshow 
test in order to assess model fit. 
An initial multivariate logistic regression model was built using the first 
univariate associations, then assessing multi-collinearity of selected 
variables.58 Univariate tests of association were conducted between the 
dependent variable, (i.e. type of medication prescribed [SR vs IR]), and the 
independent variables, potential sociodemographic predictors. A parametric 
assessment was conducted to assess the continuous variable "Age" for 
possible creation of an age category variable (see appendix for assessment). 
Potential predictor variables with a univariate test p-value of <0.15 were 
candidates for multivariate model inclusion59.  Multicollinearity was assessed 
for this model and all condition indices being less than 30 and variance 
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inflation factors being less than 8, multi-collinearity was not an issue for this 
data.   
To refine this initial model, an iterative, manual process of backwards 
elimination was used to remove variables that do not contribute to the 
prediction of the mention of SR vs IR. Variables with a Wald p-value 
assessment of p>0.10 were excluded and the AIC was examined – a lower 
AIC meaning a better fitting model. Furthermore, the c-statistic was examined 
for each model, with a preferable range of 0.6-0.8 for a model but 0.5 being 
the minimum accepted value. Goodness of fit was tested using the Hosmer-
Lemeshow test, wherein a non-significant value (p>0.05) shows the model to 
be a good fit.  Using multiple model fit tests ensured our multivariate logistic 
regression models of SR vs IR prescription were aptly fit to the data.  
Equation 1 defines the general equation of multiple logistic regression: 
Eq1: g(x) = ln (
π(x)
1−π(x)
) = 𝛼 + 𝛽1𝑥1 + 𝛽2𝑥2 +⋯+ 𝛽𝑝𝑥𝑝 
Equation 2 defines the logistic regression model that was used: 
Equation 2:   
 
Where y is the probability of having SR stimulant treatment, α is the 
intercept, and the β’s are the coefficients on the independent variables and ε is 
standard error. If analysis indicates that significant interactions exist between 
                Region Specialty Insurance race Sex age y 5 5 4 3 2 1 
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variables, they were added to the model. To interpret our odds ratios (OR), an 
OR higher than 1 indicates higher odds of having SR treatment, for example 
an OR of 1.2 means 20% higher odds of having SR treatment.  
The independent variables we investigated for inclusion in our model 
consist of the sociodemographic information available in the NAMCS (see 
appendix). The main divisions of race/ethnicity were African-American, 
Hispanic, Other, and White. Regarding insurance status, we examined 
Medicaid, Self-Pay, and other groups against Private Insurance. Age grouping 
via parametric assessment was considered, since clinical guidelines vary for 
those younger than 6 compared to 6-11 year olds and 11-17 year olds. There 
were numerous categories of physician specialty; however, the only values 
with sufficient sample size were General/Family physician, Pediatrician, 
Psychiatrist, and Neurologist.  
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CHAPTER 4 
 
RESULTS 
 Our study purpose was to examine potential predictors of healthcare 
disparities in ADHD medication. First, we used descriptive statistical analysis 
to answer the question of whether there are different proportions of medication 
prescription in different population subgroups. Then we built a logistic 
regression model to assess whether there are predictors of the prescription of 
SR vs IR stimulants. These two analyses were targeted to build upon previous 
literature and shed light on ADHD treatment evidence gaps.  
Results 
 Sample characteristics 
Out of a total of 928,629,953 office visits in 2012 and 105,548,504 
(11.37%) visits with an age of 4-17, we found 7,088,227 (7.56%) had one of 
the two diagnosis codes for ADHD (ICD-9: 314.00, 314.01). After applying our 
study inclusion criteria, we selected a total of 4,617,709 (65.15%) pediatric 
visits for our study of stimulant medication prescription. The majority of 
selected visits mentioned sustained release (SR) stimulant (n=3,431,741, 
74.32%) while the minority mentioned only immediate release (IR) stimulant 
(n=1,185,968, 25.68%). There were 2,268,862 visits (32.01%), with a 
combination of SR/IR which we included as "SR" in our analyses. 
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Regarding medications taken in the general childhood ADHD 
population (n=7,088,227), we found that 5,475,854 visits (77.25%) had a 
mention of any ADHD drug (stimulants or non-stimulants) (Table 1). SR 
stimulants were prescribed for 3,886,395 visits (54.83%), while IR stimulants 
were prescribed for 3,904,438 visits (55.08 %), and 2,540,260 had codes for 
both SR and IR stimulants (35.84 %). The most common drugs included 
methylphenidate extended-release (brand name Concerta, n=1,551,329, 
21.89%), lisdexamfetamine (n=1,395,967, 19.69%), and dexmethylphenidate 
(n=786,221, 11.09%). Methylphenidate of any sort was prescribed in 
approximately one third of pediatric ADHD visits (n=2,444,725 (34.49%). The 
brand version Adderall was frequently prescribed (n=434,082, 6.12%), as was 
the generic code mixed amphetamine salts (n=781,624, 11.03%). A small 
minority of visits had a mention of a non-stimulant medication for ADHD 
(n=858,145, 12.11%), including mentions of atomoxetine (n=178,195, 2.51%), 
guanfacine (n=343,206, 4.84%), and clonidine (n=385,038, 5.43%).   
Results 
Demographics of SR and IR Medication Groups 
To examine the SR or IR stimulant prescription study population that 
was used in the logistic model, we performed chi-square tests between each 
of the independent variables and our dependent variable, SR prescription 
(relative to IR only prescription). We found statistically significant associations 
between SR prescription and pay type, office region, anxiety, and autism 
(Table 2). The logistic model study sample, 421 unweighted visits, comprised 
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of those visits with either SR or IR medication. Of these 421 visits, 313 had SR 
prescription representing 3,431,741 weighted visits (74.35%). In this sample, 
there was roughly a 3:1 ratio of males to females (2,508,268 vs. 923,473) and 
males had a non-significantly higher rate of SR prescription (76.46% vs. 
69.05%, p=0.23). There was also a non-significant difference between the 4-6 
age group (n= 163,120, 54.92%) and the 7-11 age group (n= 1,744,109, 
73.50%) and the 12-17 group (n= 1,524,512, 78.27%, p=0.09). Relative to 
white children, who had the lowest rate of SR prescription (n=2,220,275, 
71.11%), children with a race of Black (n= 669,357, 80.59%) and Hispanic 
race (n=498,270, 80.70%) and "Other" race (n=43,838, 92.62%) had slightly 
higher proportions of SR prescription.  
Regarding payment type, the few self-pay visits had a significantly 
lower rate of SR prescription (n=105,146, 59.24%), whereas the private 
insurance (n=1,834,308, 79.75%) and Medicaid (n=1,227,480, 77.93%, 
p=0.01). populations had significantly higher proportions of SR prescription. 
The Southern region had significantly more SR prescriptions (n=1,697,891, 
80.94%) whereas the Midwestern (n=850,702, 71.54%) and Northeastern 
(n=400,037, 76.22%) regions had lower rates and the Western region had the 
lowest rate of prescriptions (n=483,111, 59.95%, p=0.05). Finally, there was a 
significantly larger proportion of SR prescription in those with a comorbid 
anxiety disorder (n=154,062, 90.34%, p=0.01) than those without anxiety. 
Furthermore, there was a significantly low rate of SR prescription in the very 
few cases of comorbid ADHD and autism (n=805, 3.22%).  
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Results  
 Multivariate Logistic Regression 
 To begin our logistic regression, we performed univariate logistic 
regression between presence of the dependent variable (SR vs IR only) and 
the independent variables, including sex, age group, race, pay type, office 
region, and physician specialty (Table 3). We found five significant univariate 
predictors of SR prescription relative to IR prescription, including age group, 
race, office region, payment type, and physician specialty. Significance was 
determined by the Wald Chi-square P-value threshold of P=0.15, considering 
individual levels of categorical variables. Regarding age, we conducted a 
parametric assessment and decided to treat this variable as a categorical 
variable in three groups (see Appendix D for parametric assessment).  
 Once we determined the univariate predictors to include, we ran an 
initial multivariate logistic regression model to attempt to predict SR vs. IR 
(Table 4). Examining the adjusted odds ratios and their 95% confidence limits, 
we see no covariate with confidence limits not including the value 1. This 
indicates that amongst these sociodemographic variables in the 421 
unweighted visit sample in the 2012 NAMCS, there are perhaps only non-
significant predictors to assess. For example, regarding age grouping, we see 
that when compared to those aged 7-11, those 12-17 are 1.69 times more 
likely to have SR prescription (versus IR) and (OR=1.691, 95% CL: [0.795, 
3.595]) and those aged 4-6 are almost 3 times less likely to receive SR versus 
IR (OR=0.359, [0.131, 0.985]). Relative to visits with a white race/ethnicity, 
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those with Black race (OR=2.183, [0.777, 6.134]), Hispanic race (OR=2.223, 
[0.457, 10.819]), and "Other" race (OR=2.717, [0.397, 18.611]) are all non-
significantly more likely to have SR versus IR only prescription. Relative to 
visits with a general or family practitioner, those with pediatricians (OR=1.725, 
[0.644, 4.618]), psychiatrists (OR=1.773, [0.590, 5.328]), and neurologists 
(OR=1.183, [0.397, 3.527] were all non-significantly more likely to prescribe 
SR vs IR only. Relative to the Northeast region, the Midwest (OR=0.794, 
[0.317, 1.991]) and the West (OR=0.684, [0.197, 2.370]) were less likely to 
prescribe SR versus IR while the South (OR=1.351, [0.507, 3.597]) was more 
likely to prescribe SR versus IR. Finally, relative to those with private 
insurance, visits with Medicaid/CHIP (OR=0.823, [0.335, 2.020], Self-Pay 
(OR=0.286, [0.060, 1.372]), and "Other" payment (OR=0.598, [0.115, 3.107] 
were all less likely to prescribe SR versus IR stimulants.  
 Regarding model fit, since proc surveylogistic does not have the ability 
to conduct the Hosmer-Lemeshow test, we examined the AIC, the C-statistic, 
and we constructed an identical initial model with proc logistic. The survey 
methods and non-survey methods produce the same odds ratio point 
estimates for predictors, however the survey methods produce a wider 
confidence interval for these estimates. We then tested the non-survey model 
fit with a Hosmer-Lemeshow goodness of fit test and found a properly 
specified initial model (p=0.1954) (see Appendix E). 
When attempting to construct a reduced multivariate model that would 
have improved model fit, we were unable to exclude any of these four 
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categorical variables without worsening model fit. First, we manually selected 
region to remove based upon its p-values being non-significant, however we 
saw a decreased C-statistic from 0.663 to 0.648, an increased AIC from 
4075966.2 to 4116137.9, and saw non-significant Hosmer-Lemeshow tests for 
both models. This indicates that this model is not improved via the removal of 
region. Similar analyses were conducted after cutting each of the other 
variables, and in each case the C-statistic and AIC worsened while Hosmer-
Lemeshow remained non-significant. Therefore, the initial model is the best 
and we do not present any final models here.  
Results 
 Sensitivity Analysis 
 Since our model counted generic drug codes, including 
"Methylphenidate" and "Amphetamine Salt Combo," as IR drugs and not SR 
drugs, we conducted a basic descriptive analysis of generic drug codes. If 
generic drugs are not counted as IR drugs, but rather excluded altogether, 
then the count of IR drug codes decreases from  314 (73.67%) to 128 
(29.52%). The two generic methylphenidate codes (n=29, 7.67% and n=193, 
46.41%) and the Adderall generic code (n=64, 14.15%) are present in the 
majority of ADHD visits. Therefore, if these codes were not included in our 
model, we would see a large reduction in sample size. In the future, a full 
sensitivity analysis of the logistic modeling will be conducted to assess the 
effect of this medication coding decision. 
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CHAPTER 5 
 
DISCUSSION 
 Attention deficit hyperactivity disorder (ADHD) is a highly prevalent 
mental health disorder in the United States and billions of dollars are spent on 
ADHD treatments each year. Our study provides an important piece of 
evidence which targets the paucity of information regarding the predictors of 
prescription of sustained release (SR) versus immediate release (IR) 
stimulants. In the current study, we have identified non-significant predictors of 
SR vs IR prescription, including race, region, age group, physician specialty, 
and payment type. While the 95% confidence limits for these adjusted odds-
ratios for all of these covariates included 1, we nevertheless can use these 
results to state that there is no stand-out disparity in the prescription of SR vs 
IR stimulants for pediatric ADHD in the United States. 
After building our logistic models, we found that age group and race 
were important predictors of SR prescription in office visits. The predictive 
relationship between older age group and SR vs IR only prescription may arise 
from the benefits of SR stimulants, including reduced stigma at school, less 
potential for misuse, slightly improved adherence, or from the prioritization of 
avoiding side effects such as agitation and anxiety. Regarding race, it is 
interesting to note that while the odds of receiving SR vs IR were over twice as 
great in Black, Hispanic, and Other race when compared to White race, there 
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is a chance these odds are 1. Further study with multiple years of the NAMCS 
dataset may provide a larger sample to reduce the variance of the 2012 data. 
Furthermore, in this initial multivariate model, we found that physician 
specialty, payment type, and office region were non-significant predictors of 
SR vs IR only. While pediatricians and psychiatrists may be 1.7 times more 
likely to prescribe SR vs IR only, it is also possible these values are close to 1. 
Further, though private insurance is more likely to prescribe SR vs IR only 
than all of the other payment types, once again there are non-significant 
intervals for Medicaid, Self-Pay, and Other. Lastly, though the South may be 
most likely to prescribe SR vs IR only, and the Midwest and West the least 
likely to prescribe SR vs IR only, these odds ratios are fairly close to 1 as well. 
In summation, though our models did not necessarily support the argument 
that SR stimulants are prescribed differently in varying sociodemographic 
groups, numerous non-significant odds-ratios were identified which may point 
towards a measurement of disparity if a larger sample size was used to build 
the model.  
Due to these negative findings, we were unable to confirm many 
previously studied disparities in ADHD medication prescription. This may be 
indicative of improvement in prescribing patterns and equal access for those in 
minority groups. Furthermore, since the sampling frame for our study is shifted 
to 2012, it is possible that new diagnostic criteria, medication options, or 
increased awareness may be different from earlier study sample frames. 
Lastly, covariates that were important in previous studies, such as sex and 
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ADHD subtype, were not found to be significantly associated with SR vs IR 
only prescription. Therefore, though we did not find stark evidence of 
disparities in SR prescription, these null findings are a useful piece of evidence 
and may encourage further consideration of ADHD healthcare disparities. 
 Our study brings useful evidence to the scholarly discussion of SR vs 
IR stimulant prescription. While other studies have conducted somewhat 
similar analyses of SR vs IR, our study was the only nationally representative 
comparison of IR and SR medication prescription with logistic modeling 
approaches. Though Lingenini et al. had a relevant comparison of IR and SR, 
their dataset was from Florida insurance claims alone. Furthermore, while Toh 
et al. studied stimulant prescriptions in the NAMCS, they did not use the most 
recent data set and their statistical analysis was limited to descriptive 
statistics. Therefore, our study provides a set of nationally representative non-
significant predictors which may guide ADHD decision-making. This may aid in 
optimizing care, highlighting differences in type of medication prescription in 
different sociodemographic groups, and examining how to reduce mental 
healthcare disparities in the United States pediatric population.  
 Combining the findings of our study and previous studies, there still 
remains an evidence gap regarding national trends in ADHD medication use. 
We could expand the current analysis of 2012 SR vs IR prescription by 
comparing non-stimulants to stimulants and comparing these with visits with 
no drug use. Furthermore, one might utilize a more recent year than 2012, 
multiple years of data, or a data source that contains patient-level longitudinal 
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data. Finally, one could expand the current analyses by incorporating multiple 
years of the NAMCS that pre-date 2012. These future analyses would all be 
complementary to the present study with some of its limitations.  
Discussion  
Limitations 
There are a few limitations to this study. First, cross-sectional study 
designs are not able to follow patients over time, thus we do not have 
indications of incident vs prevalent use or a change in medication status. 
Despite this limitation, our study design examined a large, nationally 
representative data set to draw conclusions about predictors of current 
medication status in office visits.  
One potential issue with survey data and medication coding, however, 
is that a survey of ADHD medication prescriptions may be prone to 
misclassification errors. In filling out a survey, a physician may mistakenly 
classify a prescription of an SR stimulant like Adderall XR as simply Adderall, 
which we would then reduce the magnitude any potential differences in the 
two groups. This misclassification is one example of the fallibility of physician 
reporting in surveys.  
Another medication coding issue is the assumption in our model that 
generic drugs represent IR prescriptions, not SR prescriptions, though 
generics could potentially refer to either an IR or SR formulation. To examine 
the frequency of these generic drugs, we conducted a descriptive statistical 
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analysis and found that generic codes are present in over 60% (n=286) of our 
study sample visits. Though we assume these 286 visits all have IR 
prescriptions, it is possible some fraction was actually referring to SR 
prescriptions. To address this uncertainty, future analyses should conduct a 
full sensitivity analysis by producing logistic model with verified IR and SR 
codes via brand-name drugs. 
Our current results will be generalizable only to the American pediatric 
population that visited physicians' offices in 2012. Therefore, this data is not 
necessarily representative of the American pediatric population at large, since 
different sociodemographic groups may have differing likelihoods to visit a 
physician's office. Our estimates of prevalence and drug utilization may have 
been lower than the true population levels, since previous studies have 
demonstrated lower estimates in ICD-9 based studies. Prescription of ADHD 
medication was measured by drug codes in a cross-sectional study design, 
which could not take into account adherence, persistence, or differentiate 
between prevalent and incident medication use. Finally, some confounding 
variables were not present in our data set, including socio-economic status, 
severity of ADHD symptoms, or previous medication therapy. Therefore, our 
logistic model could not adjust for these unmeasured confounders. 
Despite these limitations, our dataset and methods allowed us to target 
existing evidence gaps and to expand the evidence base for decision-makers. 
Since few studies have identified predictors for SR stimulant prescriptions, and 
none in a nationally representative dataset, our analyses may provide useful 
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evidence about prescribing patterns for pediatric ADHD. Specifically, we have 
shown that there is not stark evidence for sociodemographic disparities in the 
prescription of SR vs IR stimulants for ADHD in the United States in 2012. 
While our evidence may point towards some disparities, due to a small sample 
size and perhaps high variance data, we were unable to find significant 
predictors of SR vs IR prescription use. 
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CHAPTER 6 
   
CONCLUSION 
In this 2012 sample of physician office visits, we selected a study 
population of 4,617,709 pediatric ADHD visits with prescriptions of SR or IR 
stimulant. After conducting a logistic predictive model, we did not find 
significant sociodemographic predictors of SR vs IR prescription. First, we did 
not find that subtype of ADHD or sex were significant univariate predictors of 
SR vs IR prescription. Nevertheless, relative to 7-11 year olds, we found a 
non-significantly higher likelihood of SR vs IR stimulant prescription in those 
aged 12-17 (OR=1.691, 95% CL: [0.795, 3.595]) and a lower likelihood in 
those aged 4-6 years old (OR=0.359, [0.131, 0.985]). Non-white race non-
significantly increased likelihood of SR vs IR prescription by a factor of two, 
while those without private insurance were non-significantly less likely to have 
SR vs IR. These non-significant odds ratios may have been due to the 
changing patterns of treatment or to the varying methods to measure ADHD 
treatment.  
These analyses did not identify any strong sociodemographic predictors 
for SR versus IR stimulant drug prescription. This is a positive and noteworthy 
result especially when considering this study utilized a recent year of data that 
was nationally representative. While many other studies found disparities in 
sociodemographics, some were in older data sources and some were not 
nationally representative. Therefore, our findings may be helpful for assessing 
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the current state of American ADHD treatment. With this knowledge, 
practitioners and policy-makers may move forward with slightly more detailed 
evidence to guide future ADHD decision-making. 
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Table 1. Characteristics of Pediatric ADHD Visit Population 
 Characteristic Frequency Weighted Frequency Percent 
All Pediatric ADHD Visits 711 7,088,227 100.00 
Female 190 1,932,532 27.26 
Male 521 5,155,695 72.74 
4 to 6 years old 68 668,010 9.42 
7 to 11 years old 335 3,374,121 47.60 
12 to 17 years old 308 3,046,097 42.97 
Private Insurance 325 3,427,928 48.36 
Medicaid/CHIP 272 2,473,735 34.90 
Self Pay 36 321,547 4.54 
Other Payment Type 23 249,713 3.52 
White Race 486 4,771,295 67.31 
Black Race 120 1,229,675 17.35 
Hispanic Race 78 956,710 13.50 
Other Race 27 130,547 1.84 
Northeast Region 87 912,679 12.88 
Midwest Region 200 1,786,761 25.21 
South Region 291 3,221,211 45.44 
West Region 133 1,167,575 16.47 
General and Family 
Practitioner 
91 1,133,772 16.00 
Pediatrician 299 3,715,065 52.41 
Psychiatrist 277 1,730,501 24.41 
Neurologist 32 393,403 5.55 
ADHD Primarily Inattentive 132 1,511,043 21.32 
ADHD Combined Type 579 5,577,184 78.68 
Depression 73 664,730 9.38 
Anxiety 62 348,965 4.92 
Autism 9 80,894 1.14 
Asthma 51 601,921 8.49 
Obesity 20 249,534 3.52 
Any ADHD Drug 538 5,475,854 77.25 
Combination SR/IR 250 2,540,260 35.84 
Immediate  Release 379 3,904,438 55.08 
Adderall 44 434,082 6.12 
Adderall Generic 81 781,624 11.03 
Methylphenidate 234 2,444,725 34.49 
Dextrostat 4 27,753 0.39 
Dexmethylphenidate 73 786,221 11.09 
Sustained Release 375 3,886,395 54.83 
Adderall XR 36 342,147 4.83 
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Vyvanse 134 1,395,967 19.69 
Daytrana 11 95,483 1.35 
Ritalin SR 2 40,731 0.57 
Ritalin LA 1 3,003 0.04 
Metadate CD 7 80,956 1.14 
Methylin ER 3 22,866 0.32 
Concerta 157 1,551,329 21.89 
Focalin XR 30 387,330 5.46 
Non-stimulants 117 858,145 12.11 
Guanfacine 44 343,206 4.84 
Clonidine 59 385,038 5.43 
Atomextine 20 178,195 2.51 
 
Table 1. Characteristics of Pediatric ADHD Visit Population. This sample of ADHD visits 
includes those visits with patients aged 4-17 and with ICD-9 diagnosis codes used for ADHD: 
31400 and 31401.  
Acroynms Used: CHIP= Children's Health Insurance Program; SR = sustained release; 
IR=immediate release; ADHD= Attention Deficit Hyperactivity Disorder; LA=long acting; 
ER=extended release; XR=extended release; 
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Table 2. Comparison of Characteristics of Visits with Sustained Release versus 
Immediate Release Stimulants 
Demographic 
Group 
Sample (IR 
and/or SR) 
Freq of 
SR Rx 
Wtd Freq 
of SR Rx % SR Rx 
Pr > 
ChiSq 
Study Sample 421 313 3,431,741 74.35   
Sex   
   
0.23 
Female 119 83 923,473 69.05   
Male 302 230 2,508,268 76.46   
Age Group         0.09 
4 to 6 31 19 163,120 54.92   
7 to 11 212 152 1,744,109 73.50   
12 to 17 178 142 1,524,512 78.27   
Pay Type         0.01 
Private Insurance 205 161 1,834,308 79.75   
Medicaid/CHIP 153 116 1,227,480 77.93   
Self Pay 20 11 105,146 59.24   
Other 9 5 92,915 67.84   
Race / Ethnicity         0.30 
White 292 207 2,220,275 71.11   
Black 70 56 669,357 80.59   
Hispanic 48 41 498,270 80.70   
Other 11 9 43,838 92.62   
Office Region         0.05 
Northeast 53 39 400,037 76.22   
Midwest 127 94 850,702 71.54   
South 168 134 1,697,891 80.94   
West 73 46 483,111 59.95   
ADHD Subtype         0.68 
ADHD PI 77 54 697,115 72.19   
ADHD CT 344 259 2,734,626 74.88   
Physician Specialty     0.41 
General and Family 
Practice 
62 40 556,497 65.83 
 
Pediatrics 193 144 1,929,855 75.38  
Psychiatry 134 104 684,297 78.51  
Neurology 23 17 184,340 75.03  
Comorbidities      
Depression 38 31 288,112 80.03 0.55 
Anxiety 26 21 154,062 90.34 0.01 
Autism 4 1 805 3.22 <.0001 
Asthma 29 21 306,956 77.05 0.75 
Obesity 10 8 140,910 71.25 0.86 
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Table 2. Comparison of Characteristics of Visits with Sustained Release versus Immediate 
Release Stimulants. This study population includes those with either an IR stimulant or SR 
stimulant drug prescription, combinations were included as SR. The chi-square test was used 
to compare proportions across groups. These study subgroup estimates are nationally 
representative, calculated in SAS 9.3 via proc surveyfreq. 
Acronyms Used: CHIP= Children's Health Insurance Program; SR = sustained release; 
IR=immediate release; ADHD= Attention Deficit Hyperactivity Disorder; Rx=prescription; 
PI=primarily inattentive; CT=combined type. 
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Table 3. Univariate Logistic Regression Predicting Sustained Release 
Prescription with Potential Sociodemographic Predictors 
Analysis of Maximum Likelihood Estimates Odds Ratio Estimates 
Parameter Estimate 
Wald 
Chi-
Square Pr > ChiSq 
Point 
Estimate 
95% Wald 
Confidence 
Limits 
Sex Female (vs Male) 0.3758 1.2146 0.2704 1.456 0.746 2.841 
Age 4-6 (vs 7-11) -0.8233 2.7648 0.0964 0.439 0.166 1.159 
Age 12-17 (vs 7-11) 0.2613 0.6100 0.4348 1.299 0.674 2.502 
Race (ref=White) -- -- -- -- -- -- 
Race Black 0.5231 1.2173 0.2699 1.687 0.666 4.273 
Race Hispanic 0.5301 1.0986 0.2946 1.699 0.631 4.579 
Race Other 1.6293 3.4251 0.0642 5.1 0.908 28.637 
Pay type (ref=Private 
Insurance) 
-- -- -- -- -- -- 
Pay type 
Medicaid/CHIP 
-0.1089 0.0822 0.7743 0.897 0.426 1.888 
Pay type Other -0.6242 0.4917 0.4832 0.536 0.094 3.066 
Pay type Self -0.9967 1.8156 0.1778 0.369 0.087 1.573 
Physician Specialty 
(ref=Gen/Fam) 
-- -- -- -- -- -- 
Pediatrics 0.4630 0.9959 0.3183 1.589 0.640 3.945 
Psychiatry 0.6396 1.8444 0.1744 1.896 0.753 4.772 
Neurology 0.4445 1.0774 0.2993 1.560 0.674 3.611 
Region 
(ref=Northeast) 
-- -- -- -- -- -- 
Region Midwest -0.243 0.2645 0.607 0.784 0.311 1.98 
Region South 0.2814 0.3618 0.5475 1.325 0.53 3.314 
Region West  -0.761 2.1498 0.1426 0.467 0.169 1.292 
ADHD CT (vs ADHD PI) 0.1383 0.1566 0.6923 1.148 0.579 2.277 
Anxiety Disorder 1.2044 5.5133 0.0189 3.335 1.22 9.113 
Asthma 0.162 0.0764 0.7823 1.176 0.373 3.71 
Depression  0.3509 0.3627 0.547 1.42 0.453 4.45 
Obesity  -0.1622 0.0292 0.8643 0.85 0.132 5.464 
Table 3. Univariate Logistic Regression Predicting Sustained Release Prescription with 
Potential Sociodemographic Predictors. We assessed the univariate association between 
demographic characteristics of visits with SR drug prescriptions, relative to IR only. The 
reference group for comorbidities was those who did not have that comorbidity. For 
instance, the odds for SR prescription for those with anxiety disorder were compared to the 
odds of those without anxiety disorder. 
Acronyms Used: CHIP= Children's Health Insurance Program; SR = sustained release; 
IR=immediate release; ADHD= Attention Deficit Hyperactivity Disorder; Gen/Fam= General 
and Family Practitioner; PI=primarily inattentive; CT=combined type. 
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Table 4. Initial Multivariate Logistic Model of Sustained Release vs. Immediate 
Release Stimulant Prescription 
Analysis of Maximum Likelihood Estimates Odds Ratio Estimates 
Parameter 
Freq 
in SR Estimate 
Wald 
Chi-
Square 
Pr > Chi
Sq 
Point 
Estimate 95% Wald C.L. 
Intercept  0.2794 0.2033 0.6521 
   4-6 (vs 7-11) 212 -1.0246 3.9550 0.0467 0.359 0.131 0.985 
12-17 (vs 7-11) 178 0.5253 1.8641 0.1721 1.691 0.795 3.595 
RACE White 292 -- -- -- -- -- -- 
RACE Black 70 0.7809 2.1952 0.1384 2.183 0.777 6.134 
RACE Hispanic 48 0.7990 0.9794 0.3224 2.223 0.457 
10.81
9 
RACE Other 11 0.9994 1.0360 0.3087 2.717 0.397 
18.61
1 
REGION Northeast 
(ref) 53 -- -- -- -- -- -- 
REGION Midwest 127 -0.2304 0.2415 0.6231 0.794 0.317 1.991 
REGION South 168 0.3006 0.3617 0.5475 1.351 0.507 3.597 
REGION West   -0.3801 0.3592 0.5489 0.684 0.197 2.370 
Pay type 
(ref=Private Ins) 161 -- -- -- -- -- -- 
         Medicaid/CHIP 116 -0.1949 0.1810 0.6705 0.823 0.335 2.020 
Pay type Self 11 -1.2508 2.4469 0.1178 0.286 0.060 1.372 
Pay type Other 5 -0.5144 0.3743 0.5407 0.598 0.115 3.107 
Physician Specialty 
(ref=Gen/Fam) 40 -- -- -- -- -- -- 
Pediatrics 144 0.5451 1.1769 0.2780 1.725 0.644 4.618 
Psychiatry 104 0.5727 1.0408 0.3076 1.773 0.590 5.328 
Neurology 17 0.1678 0.0906 0.7634 1.183 0.397 3.527 
Table 4. Initial Multivariate Logistic Model of Sustained Release vs. Immediate Release 
Stimulant Prescription. A multivariate logistic regression model was constructed using 
covariates with a univariate association to SR prescription (relative to IR only). These study 
subgroup estimates are nationally representative, calculated in SAS 9.3 via proc 
surveylogistic. 
Acronyms Used: CHIP= Children's Health Insurance Program; SR = sustained release; 
IR=immediate release; ADHD= Attention Deficit Hyperactivity Disorder; Gen/Fam= General 
and Family Practitioner; Freq=Frequency; 
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Figure 1.  Literature Search Overview  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Literature Search Overview. We conducted a literature search with the 
PubMed MeSH system to identify important articles related to stimulant use for 
pediatric ADHD. Our literature search aimed to answer the question of whether or 
not SR drugs are less likely to be used in certain subgroups, relative to IR drugs. After 
removal of irrelevant articles, we found 33 studies in the literature which were 
relevant to our question about predictors of sustained release stimulant use.  
PubMed Search Terms: ("Attention Deficit Disorder with Hyperactivity/drug therapy") 
and ("healthcare disparities" OR "epidemiology" OR "Delayed-Action Preparations"  
10,851 Titles 
Reviewed 
 
140 Full Texts 
Retrieved and 
Reviewed 
EXCLUDED: ~10,000 Abstracts  
 Not population of interest (i.e children)  
 Not publication type of interest  
 Not study of epidemiology (genetics, 
imaging, history) 
 
33 studies relevant to our question 
about SR vs IR disparities in 
different sociodemographic groups 
 
EXCLUDED: 107 articles after full-text review: 
 Not population of interest 
 Not topic of interest 
 
 
~500 Abstracts 
Reviewed 
 
 
EXCLUDED: 360 Abstracts (commentary, 
opinions) 
 Literature review of clinical 
information 
 Small clinical sample studies 
 Studies of symptoms 
 Study of non-medication treatment 
(behavioral or alternative) 
 Duplicate abstract 
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Figure 2.  Study Sample Selection Flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Study Sample Selection Flowchart. To select visits for our study of predictors 
of pediatric SR prescription in 2012, we first included pediatric and ADHD visits. Next, 
we included visits with stimulant prescription, exclusive of those with concurrent 
non-stimulant drug usage. This left us with two subgroups of ADHD visits to compare 
in our logistic regression modeling.
76,630 office visits in 
2012 NAMCS 
 
 
421 pediatric ADHD 
office visits with 
stimulant mention 
EXCLUDED: ~75,917 visits  
 Not children (n=67,936) 
 No Childhood ADHD 
Diagnosis (n=7,983) 
 
SR stimulant mention 
(n=313) 
Including Combination 
SR/IR (n=181) 
 
711 pediatric ADHD 
office visits 
 
 
EXCLUDED: 290 visits 
 Non-stimulant use (n=117) 
 No medication used (n=173) 
 
IR stimulant mention 
(n=108) 
(Reference Group for 
Predictive Model) 
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Appendix A: Variables of interest and codes in the 2012 NAMCS 
Variable Title NAMCS Variable Possible Values Notes 
Diagnosis Code1, 2 
for ADHD (or 
comorbidities) 
DIAG1-DIAG3 314.00, 314.01 .00=ADD no H, 
thus IA 
.01= ADD w H, 
thus PH or CT 
Drug Entry Name / 
Generic Name 
Code3 
MED1-MED10 00001-99227 May be generic 
name or drug 
entry name 
Drug Entry Name / 
Generic Name 
Code 
DRUGID1-DRUGID10 d00000 Is generic in all 
cases and value 
starts with "d" 
Type of Payment PAYTYPER 1 Private Insurance 
3 Medicaid/CHIP 
5 self-pay 
7 Other 
 
Sex SEX 1, 2 1=Female 
2=Male 
Race RACERETH 1, 2, 3, 4 White, Black, 
Hispanic, Other 
(IMPUTED) 
Age AGE 000-099 000=  <1 
100= >100 
Geographic Region REGIONOFF 1= NE, 2= MW 
3=S, 4=W 
 
Weight Variables PATWT 
CSTRATM 
CPSUM 
 Weight, 
Stratum, and 
Cluster variables 
1. 314.00, denotes “Attention deficit disorder without mention of hyperactivity”; 314.01 
denotes “Attention deficit disorder with hyperactivity”.  
2. For full list of comorbidities, see Appendix C. 
3. Drug utilization information is captured via generic drug mentions in DRUGID1 and also the 
MED1 variable. For a comprehensive list of medication variables in the NAMCS, see the table 
below.  
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Appendix B. Drug Codes for Psychostimulant and Non-stimulant ADHD Medications in the 
2012 NAMCS 
 
Brand Name1 Generic Name1,2 
Amphetamine Psychostimulants 
'95016'='ADDERALL' 
 
'03279'='AMPHETAMINE SALT COMBO 
'd04035'='AMPHETAMINE-DEXTROAMPHETAMINE' 
'10389'='DEXTROAMPHETAMINE/AMPHETAMINE' 
 'd00803'='AMPHETAMINE' 
'01660'='AMPHETAMINE' 
'01281'='ADDERALL XR'  
 
Amphetamine, dextroamphetamine mixed salts 
 
'07406'='VYVANSE' 'd06663'='LISDEXAMFETAMINE' 
Methylphenidate Psychostimulants 
'26760'='RITALIN' '19175'='METHYLPHENIDATE' 
'd00900'='METHYLPHENIDATE' 
'02271'='RITALIN LA' MPH HCl E-R capsules 
'01234'='RITALIN-SR' MPH HCl 
'00233'='CONCERTA' MPH HCl E-R tablets 
'06172'='DAYTRANA' Methylphenidate transdermal 
'01249'='METADATE CD' MPH HCl E-R capsules 
'02018'='FOCALIN' '09384'='DEXMETHYLPHENIDATE' 
'd04777'='DEXMETHYLPHENIDATE' 
'06004'='FOCALIN XR' MPH HCl E-R capsules 
Non-Stimulant Medications 
'03080'='STRATTERA' 'd04827'='ATOMOXETINE' 
'03237'='ATOMOXETINE HCL' 
'09396'='INTUNIV (ER) 
'30777'='TENEX'' (IR) 
'd00717'='GUANFACINE' 
'97089'='GUANFACINE' 
'05895'='CATAPRES'  
'12129'='KAPVAY' 
'06985'='CLONIDINE'  
 
1Med Cod variable includes brand names and generics. MEDCOD1-8 has values 00000-99999. 
Note: Med Cod values do NOT have a lower-case "d". 
2Drug ID is the generic coding variable. DRUGID1-8 has values in the range: d00000-d99999. 
Note: DrugID values do have a lower-case "d". 
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Appendix C. Diagnosis Variables and Codes in NAMCS 
Diagnosis Variable 
Names 
Variable Values (DIAG1-DIAG3) (ICD-9) Notes 
ADHD DIAG 31400, 31401 00=predom IA 
01= PH or CT 
Depressi
on18,19 
DIAG 
DEPRN  
'29620','29621','29622','29623','29624'
,'29625','29626', 
'29630','29631','29632','29633','29634'
,'29635','29636',  
'2980', '3004-', '3091','311' 
If DEPRN = 2 then 
Depression=Y 
(From a specific 
survey question 
screening) 
Asthma DIAG 
ASTHMA 
49390, 49392, 49391 If ASTHMA = 2 
then Asthma=Y 
Obesity DIAG 
OBESITY 
2780-, 27800, 27801 If OBESITY = 2 
then Obesity=Y 
Anxiety20 DIAG '30000','30001','30002','30009','30020'
,'30021','30022','30023', 
'30029','3003-','308-
','30924','30928','30981' 
 
Autism DIAG 29900 29901  
 
Appendix D. Parametric Assessment of Age Variable vs. SR Stimulant Code 
Analysis of Maximum Likelihood Estimates 
Parameter   DF Estimate Standard 
Error 
Wald 
Chi-Square 
Pr > ChiSq 
Intercept   1 0.1969 0.4473 0.1937 0.6598 
AGEN 2 1 0.8233 0.4951 2.7648 0.0964 
AGEN 3 1 1.0845 0.5099 4.5240 0.0334 
 
Note: AGEN=1 indicates age 4-6, AGEN=2 indicates age 7-11, AGEN=3 indicates age 12-17. 
Since the beta estimates are for the three age categories are 0, 0.82, and 1.08, we are not 
confident that there is a parametric relationship with age and SR medication code.  
 
1 
0.8233 
1.0845 
0
0.2
0.4
0.6
0.8
1
1.2
4 to 6 7 to 11 12 to 17
Parametric Assessment of Age Category via 
Plotted SR Odds Ratios 
Age Category
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Appendix E. Hosmer-Lemeshow Goodness of Fit Test 
 Since proc surveylogistic cannot perform a Hosmer-Lemeshow test and is needed to 
produce nationally representative estimates for survey data, an identical model in proc 
logistic was constructed so that a test could be performed. Hosmer-Lemeshow tests are 
presented below for both the initial and reduced multivariate models. 
 
Initial Multivariate Models (Table 4) GOF: 
 
Hosmer and Lemeshow 
Goodness-of-Fit 
Test 
Chi-
Square 
DF Pr > ChiSq 
11.1121 8 0.1954 
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